High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: Comparison with a historical control

Acta Haematologica

Volumn 115, Issue 1-2, 2006, Pages 9-14

  Capria, Saveria ^a   Petrucci, Maria Teresa ^a   Pulsoni, Alessandro ^a   Ribersani, Michela ^a   Baldacci, Erminia ^a   De Propris, Maria Stefania ^a   Meloni, Giovanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autologous stem cell transplantation; High dose idarubicin; Multiple myeloma

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; MELPHALAN; MORPHINE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGIC CYSTITIS; HUMAN; HYPOCALCEMIA; INFECTION; LIVER FAILURE; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; PAIN; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTE; TOXICITY;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DACARBAZINE; FEMALE; GRAFT SURVIVAL; HUMANS; IDARUBICIN; INFECTION; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; MULTIPLE MYELOMA; NEUTROPENIA; NIMUSTINE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 31144453003     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089459     Document Type: Article

References (20)

1. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma: new biological insights and advances in therapy. Blood 1989; 73:865-879.
2. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 1994;330:484-489.
3. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995;85:3077-3085.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
5. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-763.
6. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J: Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
7. Lahuerta JJ, Martinez-Lopez J, Grande C, Blade J, de la Serna J, Alegre A, Garcia-Larana J, Caballero D, Sureda A, de La Rubia J, Alvarez AM, Marin J, Escudero A, Conde E, Perez-Equiza K, Garcia Ruiz JC, Moraleda JM, Leon A, Bargay J, Cabrera R, Hernandez-Garcia MT, Diaz-Mediavilla J, Miguel JS: Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 2000;109:138-147.
8. Muus P, Donnelly P, Schattemberg A, Linssen P, Minderman H, Dompeling E, de Witte T: Idarubicin related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 1993;20:47-52.
9. Raemaekers J, de Witte T, Schattemberg A, van der Lely N: Prevention of leukemic relapse after transplantation with lymphocyte-depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplant 1989;4:167-171.
10. Jerjis S, Roovers E, Muus P, Shaap N, de Witte T: Idarubicin to intensify the conditioning regimen of autologous bone marrow transplantation for patients with acute myeloid leukaemia in first complete remission. Bone Marrow Transplant 1998;22:13-19.
11. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsioni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Maiolino I, Mandelli F: Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study. Haematologica 2000;85:52-58.
12. Meloni G, Capria S, Trasarti S, Ferrazza G, Micozzi A, Petrucci MT, Simone F, Trisolini SM, Mandelli F: High-dose idarubicine, busulphan and melphalan as conditioning regimen for autologous blood stem cell transplantation in multiple myeloma. A feasibility study. Bone Marrow Transplant 2000;26:1045-1049.
13. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornelissen JJ, Croockevit AJ, Dekker AW, Fibbe WE, Lowemberg B, van Marwik Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM: Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. B J Haematol 1999;105:127-130.
14. Lo Coco F, Mandelli F, Diverio D, Alimena G, De Fabritiis P, Meloni G, Cedrone M, Frontani M, Guerrasio A, Saglio G: Therapy induced Ph1 suppression in chronic myeloid leukaemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. Bone Marrow Transplant 1990;6:253-258.
15. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979, p 38.
16. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
18. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Togel F, Wittkowsky G, Kuse R, Zander AR: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-760.
19. Patriarca F, Sperotto A, Filì C, Zaja F, Prosdocimo S, Fanin R: Early chemosensitivity to VAD regimen predicts a favourable outcome after autologous stem cell transplantation in multiple myeloma. Haematologica 2002;87:779-781.
20. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.